期刊文献+

乳腺癌血管生成与预后的相关性 被引量:1

STUDY OF THE CORRELATION BETWEEN ANGIOGENESIS AND PROGNOSIS OF BREAST CARCINOMA
下载PDF
导出
摘要 随访 92例原发性乳腺癌术后病例。在石蜡包埋肿瘤组织中 ,以免疫组化方法检测血管内皮生长因子 (VEGF)表达和肿瘤内微血管密度 (MVD) ,并对二者进行相对定量观察。结果无瘤生存 (RFS)时间单变量分析显示 ,在淋巴结阴性组中 ,高MVD组比低MVD组的RFS时间降低 ,差异有显著性意义 (P <0 .0 5 )。RFS多变量分析表明 ,在淋巴结阴性组和全部病例组中 ,MVD是一个独立的预后因素 (P <0 .0 5 0 .0 1)。此外 ,VEGF表达程度与MVD之间有显著的正相关关系 (P <0 .0 1)。结果显示 ,VEGF在原发性乳腺癌血管生成中起着关键作用 ;VEGF和MVD与乳腺癌的生物学行为关系密切 。 92 specimens from patients with invasive ductal carcinoma were investigated. The expression of vascular endothelial growth factor (VEGF) was demonstrated by immunocytochemical staining with an antibody against VEGF and was quantitatively estimated by using computerized image analysis system. Vessels were immunohistochemically highlighted by using an antibody to CD34, and microvessel density (MVD) was quantified. The postoperative survey in univariate analysis showed that the relapse-free-survival (RFS) time of patients with more than 87 microvessels in single microscopic field was significantly worse compared to that of patients with less than 87 microvessels in node-negative patients (P<0.05). Multivariate analysis confirmed that MVD was an independent prognostic indicator for RFS in node-negative patients and all patients (P<0.05~0.01). In addition, there was a closely positive correlation between VEGF and MVD (P<0.01). The results suggested that VEGF plays crucial roles in the promotion of angiogenesis in primary breast carcinoma. VEGF and MVD are closely correlated with biological behavior of primary breast carcinomas. MVD can provide a useful message in predicting the recurrence or metastasis of tumors.
机构地区 解放军总医院
出处 《解放军医学杂志》 CAS CSCD 北大核心 2001年第3期226-228,F004,共4页 Medical Journal of Chinese People's Liberation Army
关键词 乳腺肿瘤 预后 新生血管化 病理性 breast neoplasms prognosis neovascularization, pathologic
  • 相关文献

参考文献9

  • 1[1]Folkman J. What is the evidence that tumors are angiogenesis dependent ? J Natl Cancer Inst, 1990, 82:4
  • 2[2]Toi M, Inada K, Suzuki H et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat, 1995, 36: 193
  • 3[3]Weidner N, Semple SP, Welch WR et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med, 1991,324:1
  • 4[4]Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat, 1995,36: 169
  • 5[5]Dovrak HF, Harvey VS, Estrella P et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma gereration and wound healing. Lab Invest, 1987,57: 673
  • 6[6]Toi M, Kondo S, Suzuki H et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 1996,77: 1101
  • 7[7]Liotta LA, Stracke ML. Tumor invasion and metastasis: biochemical mechanisms. In: Lippman ME, Dickon RB, eds. Breast Cancer: Cellular and Molecular Biology. Boston: Kluwer Academic Publishers, 1988: 223-238
  • 8[8]Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density , p53 expression, tumor size and peritumoral lymphatic invasion are relevant prognostic markers in node-negative breast cancer. J Clin Oncol, 1994,12: 454
  • 9[9]Martin L, Green B, Renshaw C et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer, 1997,76: 1046

同被引文献21

  • 1[1]Verheul HM, Panigraphy D, Yuan J, et al. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits[J]. BrJ Cancer, 1999, 79(1): 114~118
  • 2[3]Liu J, Razani B, Tang S, et al. Angiogenesis activators and inhibitors differently regulate caveolin-1 expression and caveolae formation in vascular endothelial cells angiogenesis inhibitors block vascular endothelial growth factor induced down regulation of caveolin-1 [J]. J Biol Chem, 1999, 274(22): 15781 ~ 15785
  • 3[4]Raje N, Kenneth C. Thalidomide and immunomodulatory drugs as cancer therapy[J]. Oncology, 2002, 14(6): 635~640
  • 4[7]Singhal S, MehtaJ, Desilan R, et al. Antitumor activity of thalidomide in refractory multiplemyeloma [J]. N EnglJ Med, 1999, 341(21):1565~1571
  • 5[9]Figg WD, Arlen P, Gulley J, et al. A randomized phase Ⅱ trial of docetaxel (taxotere) plusthalidomide in androgen-independent prostate cancer[J].Semin Oncol,2001, 28(suppl 15): 62~66
  • 6[10]Singhal S, Mehta J. Thalidomide in cancer [j]. Biomed Pharmacother, 2002, 56(1): 4~12
  • 7[11]Chaudhry V, Gornblath DR, Freimer M, et al. Thalidomide-induced neuropathy[J]. Neurology, 2002, 59(12): 1872~1875
  • 8[12]Kakimoto T, Hattori Y, Okamoto S, et al. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome[J]. Jpn J Cancer Res, 2002, 93 (9): 1029 ~ 1036
  • 9[13]Kerbel RS.Tumor angiogenesis: past, present and the near future[J]. Carcinogenesis, 2000, 21 (3): 505~515
  • 10[17]Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects [J]. Invest New Drugs, 1997,15(3): 175~185

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部